Core Viewpoint - The 76th American Association for the Study of Liver Diseases (AASLD) annual meeting highlighted significant advancements in hepatitis B treatment, particularly through the innovative drug Hepcludex developed by Shanghai Hepu Pharmaceutical, which has shown promising results in clinical trials [1] Group 1: Clinical Trial Results - Hepcludex has achieved breakthrough progress in its Phase II randomized double-blind clinical trial for chronic hepatitis B [1] - The drug demonstrated the ability to reverse interferon resistance in patients with "big three positive" hepatitis B, a significant milestone in treatment [1] - Some patients in the trial achieved cccDNA clearance, meeting the highest international standard for hepatitis B cure known as sterilizing cure [1]
国内乙肝创新药物获突破性进展
Zheng Quan Shi Bao Wang·2025-11-10 08:27